Retractable Technologies, Inc.

As of May 15, 2023, Retractable Technologies, Inc. is considered overvalued and risky due to negative earnings and poor return metrics, with key ratios indicating underperformance compared to peers and a significant long-term decline in stock value.

As of May 15, 2023, Retractable Technologies, Inc. is considered overvalued and risky due to negative financial metrics, including a Price to Book Value of 0.26, an EV to EBITDA ratio of 0.96, and a Return on Equity of -32.28%, alongside a one-year stock return of -44.44% compared to the S&P 500's 10.26%.

As of June 9, 2025, the technical trend has shifted to a moderately bearish stance, indicated by bearish weekly MACD, daily moving averages, and KST signals, along with mildly bearish Bollinger Bands on both weekly and monthly charts.

As of March 2022, the management team of Retractable Technologies, Inc. includes Mr. Thomas Shaw as Chairman, President, and CEO, and Mr. John Fort as Vice President, CFO, Treasurer, and Director, along with several independent directors.

Retractable Technologies, Inc. designs and manufactures safety medical products for the healthcare sector. As of March 2025, it reported net sales of $8 million and a net loss of $11 million, with a market cap of $19.56 million.

As of Jun 18, Retractable Technologies, Inc. has a market capitalization of 19.56 million and reported net sales of 33.75 million with a net profit of -22.81 million over the latest four quarters. Shareholder's funds are 87.17 million, and total assets amount to 160.72 million.